[Homosexual pedophilia and functional networks - An fMRI case report and literature review].

Pedophilia is a complex bio-psycho-social disorder often associated with serious offending. Knowledge about neurobiological correlates that could serve as diagnostic and maybe even as prognostic markers is limited. FMRI examination, which shows neuronal activation in vivo and therefore represents a neurobiological correlate, was not done in pedophilia so far.

[Medicamentous therapy of alcoholic polyneuropathy. Randomized double-blind study comparing 2 vitamin B preparations and a nucleotide preparation].

In a randomized double-blind study involving 303 patients with alcoholic polyneuropathy the efficacy and tolerability of the combinations thiamine/pyridoxine, benfotiamine/pyridoxine, and the nucleotides of cytidine and uridine administered orally for 21 days were compared. Pain and paraesthesia, measured on a visual 10-cm-long analogue scale, as also pallaesthesia and the strength of the dorsiflexion and plantar flexors of the foot, clearly improved in all treatment groups. Clinically relevant differences in efficacy were not observed.

[Pseudo-hallucinations after long-term lithium treatment].

A 58-year old women with a history of recurrent depressive episodes had been on successful prophylaxis with lithium carbonate in controlled therapeutic dosage for 11 years. At this time she experienced with increasing frequency mostly visual, sometimes auditory pseudohallucinations which disappeared after stopping the lithium medication. Because a subsequent depressive episode did not respond to tricyclic antidepressants or to a MAO-inhibitor the patient was again prescribed lithium.

Subclinical hyperthyroidism: physical and mental state of patients.

We investigated whether subclinical hyperthyroidism [subnormal basal thyroid-stimulating hormone (TSH) level, attenuated TSH response to thyrotropin-releasing hormone (TRH) stimulation, peripheral thyroid hormones within normal range] is accompanied by physical and mental changes. Thirty-five subclinically hyperthyroid patients (27 female, 8 male) were compared with 60 overtly hyperthyroid patients (51 female, 9 male) and with 28 euthyroid control patients (18 female, 10 male) with respect to physical symptoms, affective state, short-term memory, ability to concentrate and psychomotor performance. Patients with subclinical hyperthyroidism ranged between the other two groups.

Trimipramine--an atypical neuroleptic?

Trimipramine and clozapine show some similarities in their receptor binding profiles. Since both have the same affinity for the D2 receptor and since the affinity for this receptor correlates closely with the antipsychotic potency of a drug, an antipsychotic efficacy of trimipramine in acute schizophrenia could be expected. Therefore 28 schizophrenic patients in an acute phase were treated with trimipramine up to 400 mg/d in an open clinical trial.

[The role of TSH psychological and somatic changes in thyroid dysfunctions].

The characteristic psychic and somatic features found in patients with overt hyper- or hypothyroidism are usually attributed to elevated or diminished levels, respectively, of thyroid hormones. This concept does not sufficiently explain our previous investigations in which the same symptoms, albeit attenuated, were also seen in patients suffering from so-called latent disturbances of thyroid function. This state of disorder, however, exhibits normal concentrations of peripheral thyroid hormones.

Sequential psychological testing during the course of autoimmune hyperthyroidism.

Although the psychological disturbances accompanying Graves' disease are well known, the time required for normalisation of these disturbances during antithyroid drug treatment is not known. Therefore sequential psychological testing during the course of Graves' disease was done. There are also contradictory results concerning the possible correlation of neurophysiological and psychological test results during the course of Graves' disease with thyroid hormone values.

[Correlation of "latent hyperthyroidism" with psychological and somatic changes].

The study reported here was undertaken to establish the degree to which a person in a preclinical state of hyperthyroidism, with (by definition) euthyroid T3 and T4 levels but suppressed TRH on testing, already exhibits psychological changes and clinical symptoms. Two groups of 20 patients each, with clear clinical and preclinical hyperthyroidism (as defined by laboratory parameters), were studied, as well as a group of 20 controls. The subjects' psychological state of mind was investigated using self-rating scales, including the state-trait-anxiety inventory (STAI), "Befindlichkeits"-Skala (Bf-S'), depression scale (D-S'), and a list of adjectives (EWL-K) with 14 different aspects of affective moods.

The metabolic fate of 2H-labelled propafenone in man.

The metabolism of propafenone was studied in three humans by using 300 mg of the deuterated compound given orally. The excretion of propafenone and its metabolites was assessed by measuring the deuterium content in the excretion products by means of a microwave plasma detector. At selected times the metabolic pattern in plasma, urine, bile and feces was determined.

Investigations on the pharmacokinetics of propafenone in man.

The pharmacokinetics of propafenone (Rytmonorm) was studied in 19 healthy volunteers. Propafenone was given intravenously (commercial ampoules of 70 mg) and orally in different doses (150, 300, 450 mg) and forms (solution, commercial film tablets). The results show a dose dependence of bioavailability and maximum plasma concentrations after oral application with over-proportionate increase at higher dose levels yielding bioavailabilities up to 40-50% with single applications of 450 mg.

Pharmacokinetics of low molecular (monovalent) dextran (Dx 1) in volunteers.

Dextran-induced side effects were attributed to preformed antibodies that cross-react with dextran. These antibodies can be blocked by monovalent haptens (dextrans 1) in animals. Dextran 1 is also well tolerated in humans.

Absolute bioavailability of amezinium. A cross-over study after i.v. and p.o. application.

The absolute bioavailability and pharmacokinetics of 4-amino-6-methoxy-1-phenyl-pyridazinium methyl sulfate (amesiniummetilsulfate, LU 1631, Regulton), in the following briefly called amezinium, were examined following i.v. injection (10 mg) and single p.

[Activation of the complement system with clinical dextran (Macrodex 6%) in 10 patients in a cross-over design against 0,9%-NaCl].

The possibility of activation of the complement system with clinical Dextran 60 (500 ml Macrodex 6% infusion) as compaired with 500 ml 0.9% NaCl was investigated within a one week interval in 10 volunteers of both sexes in a cross-over design. Anaphylactoid symptoms, which would indicate a release of biological activities, were not induced by Dextran 60 or 0.

Pharmacokinetics of potassium ampicillin.

Potassium ampicillin was studied in normal volunteers. It was administered orally to a group of five male subjects in a single dose of 500 mg. Peak plasma concentrations (2.

Clinical trial of droperidol for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.

In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured using Haase's graphopathological test) and the maximum dose were determined. The neuroleptic threshold dose was 18.5 mg/day (SD = 8.

The effect of the composition of food on the absorption of sulfameter.

The present investigation is concerned with the influence of the composition of food on the absorption of sulfameter. Six physically healthy patients each were given 2 g of sulfameter simultaneously with a high lipid, high protein and high carbohydrate test meal. This experiment was designed as a threefold crossover study, and there was a randomized assignment of patients to the different conditions.

Open study with bromperidol (C-C 2489), a new neuroleptic, for the determination of the neuroleptic threshold and the neuroleptic-therapeutic range.

In an open study involving 30 schizophrenic patients the neuroleptic threshold dose (measured via Haase's graphopathological test), the maximum dose, and the maintenance dose were determined. The neuroleptic threshold dose was 5.6 mg/day (0.

The pharmacokinetic aspects of therapy with psychotropic agents.

This contribution is concerned with a critical appraisal of the concept that plasma levels of psychotropic agents govern their pharmacodynamic action. In this regard, there are at least three problems: 1. identification of the chemical course of reaction between the introduced pharmacon and its resultant metabolites in reference to the totality of the organism and its biochemical reaction pattern; 2.

Neuroleptic potency of bromperidol.

The following statements can be made on the basis of our study. 1. The butyrophenone bromperidol is an absolutely effective drug of the series of very high-potency neuroleptics, with a mean neuroleptic threshold dose of 5.